金吾财讯 | 再鼎医药(ZLAB)盘中一度涨超24%，截至发稿，涨13.75%，报32.92美元。消息面上，再鼎医药在2024年EORTC-NCI-AACR(ENA)研讨会上展示了ZL-1310全球1a期临床研究数据。数据显示，ZL-1310在广泛期小细胞肺癌中展现出良好的客观缓解率和安全性。在复发的广泛期小细胞肺癌(SCLC)患者中，ZL-1310在所有测试剂量水平的客观缓解率(ORR)达74%。
此外，摩根大通将再鼎医药目标价从38美元上调至44美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.